The Effect of Combining Urosteptin with High-Dose Ambroxol in Treating Severe Pneumonia

ZHOU Xiang; LAI Xiaodong

doi:10.14033/j.cnki.cfmr.2025.30.014

Abstract：Objective:To investigate the efficacy of combining usultadine with high-dose ambroxol in the treatment of patients with severe pneumonia.Method:A total of 112 patients with severe pneumonia admitted to Sanming First Hospital from January 2021 to December 2024 were randomly assigned using a random number table method to either a control group or a study group,with 56 patients in each group.The control group received ustadine plus conventional-dose ambroxol,while the study group received ustadine plus high-dose ambroxol.The efficacy of the two treatment groups and the incidence of drug-related adverse reactions were compared.Additionally,changes in blood gas parameters,inflammatory cytokine levels,and the time to resolution of disease symptoms before and after treatment were evaluated.Result:The study group demonstrated superior clinical efficacy compared to the control group,with statistically significant differences(P<0.05).The incidence of drug-related adverse reactions showed no statistically significant difference between the two groups(P>0.05).Post-treatment,the study group exhibited significantly better blood gas indexes compared to the control group,with all differences statistically significant(P<0.05).After treatment,the levels of inflammatory-factors in the study group were all lower than those in the control group,with statistically significant differences(P<0.05).The time to resolution of fever,cough,sputum production,and pulmonary rales was shorter in the study group than in the control group,with statistically significant differences(P<0.05).Conclusion:The combination therapy of ustadine and high-dose ambroxol demonstrates proven efficacy in treating patients with severe pneumonia without increasing adverse reactions,and promotes improvement in blood gas parameters and inflammatory markers.